Tenofovir Antiviral Therapy Following Transarterial Chemoembolization for HBV Related Hepatocellular Carcinoma
Status:
Terminated
Trial end date:
2018-02-01
Target enrollment:
Participant gender:
Summary
Hepatocellular carcinoma (HCC) is one of the most common solid cancers worldwide, and chronic
hepatitis B virus (HBV) infection is the most common etiology of HCC in Asia. Transarterial
chemoembolization (TACE) is the standard treatment for patients with unresectable HCC in the
BCLC intermediate stage, but the HCC recurrence rates and long-term mortality rates are quite
high. These intermediate-staged HCC patients usually need repeated TACE due to tumor
recurrence, and they may die of HCC progression or liver decompensation after repeated TACE.
Improved liver function and decreased liver disease progression due to oral antiviral therapy
have been proven to be effective for chronic hepatitis B, and oral antiviral therapy may keep
better liver reserve and provide better chance for HCC patients received TACE. In addition,
chronic HBV infection is one of the most important factors for HCC development, and antiviral
therapy can improve the outcomes after curative treatment. However, the evidence of improving
outcomes of HCC patients underwent TACE by oral antiviral therapy is lacking. Moreover,
Tenofovir Disoproxil Fumarate (TDF) is one of the most potent oral antiviral agents, and its
safety and very low long-term viral resistance rate have been also reported. There is no
study to evaluate the impacts of TDF for HBV-related HCC patients underwent TACE. Until now,
routine antiviral therapy for HBV-related HCC patients underwent TACE has still not been
recommended by current guidelines. The hypothesis of this study is that a potent oral
antiviral therapy for patients with HBV-related HCC patients receiving TACE improve patients'
outcomes